Last month, DeFloria Inc.—a joint venture between Ajna BioSciences PBC and Charlotte’s Web Holdings Inc.—announced a milestone in its development of an oral multi-cannabinoid drug for the treatment of symptoms of autism spectrum disorder (ASD). In a first for botanical drug development, not just cannabinoid drugs, DeFloria received FDA Investigational New Drug (IND) application clearance…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
